Please read these articles
http://boards.fool.co.uk/Message.asp?mid=7842473

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

http://www.medisys-group.com/Prelims_5_061202-1.pdf'

http://www.safetysyringesplus.com/info.htm

This has massive potential from products other than FUTURA which if it takes off will be the iceing on the cake.Let me give you the highlights from this Mays interims;

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf (see page 4)

http://www.research.reuters.co.uk/Research/Earnings.asp?ticker=MDY.L&country=GB&mxid=100068815&companyName=MEDISYS+PLC&sym=RE
VERY IMPORTANT MESSAGE TO ALL BUYERS/HOLDERS - PLEASE LISTEN

http://www.wallstreetreporter.com/profiles/Medisys.html

LOL !

I'm am actually now getting very excited by MDY ! Why ?

Well when the stock market was down heavily the share was trading as high as 26p.News of the split with Smiths and the patent problem have driven the price down 50% !

The Futura issue which everyone has been waiting for has now been resolved and lets just anticipate that the news on the patent front is unfounded.During this downtime we also went EBITDA positive.

Now those factors alone should really see us moving back to the recent highs if not higher and with the possibility of additional good news we could all be looking at a very Merry Christmas.

And it helps if you bought more at the depressed prices like I had the kahunas to do!

Roll on 20p, 30p, 40p, etc, etc (ramp away until my eyes bleed!!!!!)

We just need to hear that a major international distribution company has come on board for this to sky rocket IMHO. Then we can wait in anticipation for the full results after all the products are on line and rolling off the shelves! NICE!!!!

AGM this week ?

Thursday Happy1 :)

Gotta be more good news at the AGM. I'm hoping the Smiths debacle did not effect earnings and turnover too much. Did Mdy ever see the cash Smiths owed them for the contract termination?

Roll on tomorrow!

Looking very good today.After a 28% rise we had a bit of profot taking and are now firmly into an upward trend.

RNS Number:9201W
Medisys PLC
25 March 2004



For Immediate Release 25 March 2004


Medisys PLC
("Medisys" or "the Group")


FirstOrder For NewTek Blood Glucose Monitor Received From Wal-Mart


Further to the AGM Statement released earlier today, Medisys announces that it
has now received the first purchase order for its NewTek product from Wal-Mart,
the Group's exclusive USretail partner for the product.


The purchase order was received overnight and will be fulfilled from existing
inventory. It is anticipated that shipping will commence today.


Dave Conn, Chief Executive, commented: "The receipt of our first order from
Wal-Mart is a major milestone for the Group. NewTek is the first ever fully
integrated, disposable blood glucose monitoring system offering a new level of
convenience to the user. We are excited by its prospects as part of Wal-Mart's
well established ReliOn(R) brand, which offers value based products to their
diabetes customer."


- Ends -

Enquiries:


Medisys PLC 020 7563 5200
David Conn, Chief Executive Officer

Michael Barry, Chief Financial Officer

A very robust defence claim to the Roche problem !

Now we are opening up the diabetese market into Europe.Massive new revenue channels !

Moving into Europe today ! The good news just keeps on coming !!!http://www.uk-wire.com/cgi-bin/articles/200404300700111754Y.html

We also have interims comming up and the $ has been strengthening against sterling. This will soon have a re-rating IMO.

Another snippet of news is that NMT have sorted the patent claim with RTI but are now unable to sell in the USA.Who will Roche now use ?

Less competition.Let the good times roll !

Techmark movers: Medisys up, Antisoma down

Fri 30 Apr 2004


LONDON (SHARECAST) - Medisys picked up after it received notification it can put the CE mark to its Advance Micro-draw blood glucose monitoring product which will allow it to market the product within the EU.

The company says it is selling the Advance Micro-draw product by the mail order in the US at present.

"Strategic partnership opportunities with suitable potential European marketing partners are currently being explored with a view to maximising market penetration of the product," it said.

Chart wise looks ripe for a positive breakout.

Thanks to Lisa

Roche's Taq patent held unenforceable for inequitable conduct
[Published: 20 May 2004 Source: Anti-Infective Drug News from Espicom]

Judge Walker of the US District Court in California has ruled that Roche's patent (No. 4,889, 818) covering Taq DNA polyermase is unenforceable due to inequitable conduct. The Judge also dismissed all four of Roche's breach of contract claims and sought additional evidence before making a conclusive ruling relating to the unenforceability of the PCR patents.

This case comprises a series of six intentional and material misrepresentations to the PTO as part of Roche's efforts to procure the patent, including the fabrication of data and experiments. In noting that the misstatements made by the patent applicants were both material and "made with intent to deceive the PTO," Judge Walker ruled that "the equities warrant a conclusion that the patentee has engaged in inequitable conduct . . . and the appropriate remedy is to hold unenforceable the patent obtained by inequitable conduct." The court then dismissed all of Roche's claims related to the Taq patent, rendering it unenforceable against Promega and the public, including the many healthcare institutions and universities using Taq in their research and clinical diagnostics testing.

In addition, the Court concluded that "the inequitable conduct that occurred during the prosecution of the '818 patent bears an immediate and necessary relation" to the Taq DNA polymerase license that Promega had entered into. On that basis, the Court dismissed all four of Roche's breach of contract claims.

************************

Have a great weekend one and all!

Lisa :)

I think in 6 months MDY will be in profit. Then the fireworks start. I am using the dips to add and feel that MDY is really turning itself around but has lost credibility.


A real shame but those that BUY and HOLD will be rewarded in the future.

At sub 10p a bargain not to be missed !

Now starting to recover.

Ideal time to add at this level.

nigel_man - 23 Jun'04 - 10:48 - 13069 of 13073


US Distributor of Futura Safety Syringe - Briggs Corporation?
see catalog entries for Futura 3cc syringes.

http://www.briggscorp.com/e2wItemQuickSearch.aspx?searchText=futura%20safety%20syringe

New distributor of NewTek and Hypoguard range outside of the US - Artic Medical!!!

http://www.amlonline.com/MainSite/html/news.html
http://www.amlonline.com/MainSite/index.html
http://www.amlonline.com/MainSite/html/diabetes_care.html